Akorn signed an exclusive supply agreement with PrimaPharm to supply Hydase, a branded NDA product indicated as an adjuvant to increase the absorption and dispersion of other injected drugs.
Hydase will be manufactured by PrimaPharm, owner of the NDA. Akorn will have exclusive marketing and distribution rights in the U.S. and Puerto Rico. Akorn expects to launch the product in the first half of 2007.
The companies report that the total U.S. market size for Hyaluronidase Injection is $8.6M, according to 2006 IMS data. Hydase formulation is preservative free and does not contain thimerosal.
“This is a niche, NDA product that fits our marketing strategy in both our hospital and ophthalmic business segments,” states Arthur S. Przybyl, Akorn’s president and CEO. “The fact that Hydase does not contain thimerosal is an important competitive advantage over other marketed hyaluronidase drugs.”